DKN-01 is a Monoclonal Antibody owned by Leap Therapeutics, and is involved in 13 clinical trials, of which 6 were completed, 6 are ongoing, and 1 is planned.

DKN-01 acts by inhibiting dickkopf-1 (Dkk-1). Elevated levels of Dkk-1 in bone marrow plasma and peripheral blood are associated with the presence of osteolytic bone lesions. Dkk-1 interacts with low density lipoprotein receptor related protein (LRP5/6) and inhibits the Wnt pathway. Anti-DKK1 monoclonal antibodies bind to and inhibit Dkk-1, restores the Wnt pathway signaling resulting in osteoblast differentiation and activation within the bone matrix and the reversal of tumor-induced osteolytic disease and ameliorates the condition.

The revenue for DKN-01 is expected to reach a total of $882m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the DKN-01 NPV Report.

DKN-01 was originated by Eli Lilly and Company and is currently owned by Leap Therapeutics.

DKN-01 Overview

DKN-01 (LY-2812176) is under development for the treatment of bile duct cancer, esophageal cancer, fallopian tube cancer, adenocarcinoma of the gastroesophageal junction, epithelial ovarian cancer, peritoneal cancer, endometrial cancer, carcinosarcoma (uterine cancer), gallbladder cancer, metastatic castration-resistant prostate cancer, colorectal cancer, advanced gynecological cancers and extrahepatic bile duct cancer. The drug candidate is administered intravenously. It is a monoclonal antibody targeting dickkopf homolog 1 (Dkk-1). The drug candidate was also under development for the treatment of relapsed or refractory multiple myeloma and non-small cell lung cancer.

Leap Therapeutics Overview

Leap Therapeutics is a clinical-stage biopharmaceutical company that develops novel therapeutics to treat patients with different types of cancer. The company’s pipeline products include DKN-01. DKN-1 is a monoclonal antibody that targets the Dickkopf-1 (DKK-1) protein, intended for the treatment of gastroesophageal cancer, prostate cancer and gynecologic cancer. The company has an agreement with BeiGene Ltd for development rights and commercialization of DKN-01 in Australia, Asia (excluding Japan) and New Zealand. Leap Therapeutics is headquartered in Cambridge, Massachusetts, the US.

The operating loss of the company was US$41.4 million in FY2021, compared to an operating loss of US$28.5 million in FY2020. The net loss of the company was US$40.6 million in FY2021, compared to a net loss of US$27.5 million in FY2020.

Quick View – DKN-01

Report Segments
  • Innovator
Drug Name
  • DKN-01
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
Key Companies
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.